PharmTech Weekly Roundup-May 8, 2026

This week, the industry saw a push for proactive risk management, the rise of advanced modalities, and the integration of flexible, tech-enabled infrastructure.

Whether it is navigating the complexities of genetic medicines or addressing skilled labor shortages, the industry is moving away from rigid, legacy systems toward modular, automated, and sustainable frameworks. The following stories highlight how the sector is evolving to meet modern clinical and commercial demands.

In investment news this week, Eli Lilly’s $4.5 billion expansion of its Indiana manufacturing campus underscores a massive push for domestic capacity in advanced modalities, including genetic medicines and high-volume metabolic treatments for obesity.

In conference coverage, PharmTech spoke with Dave Schoneker to learn more about IPEC-Americas’ Risk-Based Excipient Framework and the related workshop conducted at Excipient World, which was held from May 4-6 in Nashville this year. The new risk-based framework and decision-tree model from IPEC-Americas aims to streamline the development of new excipients by systematically evaluating safety, quality, and market acceptance risks.

Our coverage of INTERPHEX 2026 continued with interviews on lean and sustainable design, media and buffer strategies, robotics, and modularization.

Leslie Weaver and George Hunt of IPS talked about how integrating “design for disassembly” and lean principles into capital projects allows pharmaceutical manufacturers to build more adaptable, sustainable facilities that can evolve with changing production needs rather than requiring total demolition.

Avi Nandi of SK pharmteco talked about how bringing media and buffer manufacturing on-site offers CDMOs a strategic way to de-risk supply chains, reduce lead times, and improve sustainability through increased productivity in cell and gene therapy production.

Christa Meyers and Todd Vaughn of CRB explained how increasing regulatory expectations are driving the adoption of robotics in aseptic cores to minimize human intervention, thereby reducing contamination risks and improving the efficiency of environmental monitoring.

IPS’ Richard Sandersonstressed that modularization and off-site fabrication are becoming essential construction strategies to mitigate the impacts of regional skilled labor shortages and enhance proactive risk management for large-scale pharmaceutical projects.

And finally, Dirk Schuster, sales director Pharma at groninger & co. GmbH, provided his insights on how artificial intelligence is transforming the visual inspection of injectable drugs by linking complex process and image data to detect subtle deviations, particularly in sensitive, high-viscosity biologic formulations.

As this week’s news stories and interviews show, the future of the industry lies in balancing rapid innovation with robust, data-driven controls. By embracing these technological and structural shifts, manufacturers can ensure more reliable, scalable, and compliant pathways to the patient.

Be sure to join us again next week. Thank you for watching.